BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 10, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 28, 2014
View Archived Issues
In cellulo synthesis of potent oligomeric inhibitors of disease-causing RNAs
Read More
Recent FDA orphan drug designations for cancer treatments
Read More
OncoEthix to begin phase Ib trial of OTX-015
Read More
Lucitanib study in squamous non-small cell lung cancer enrolls first patient
Read More
Cellceutix reports positive data from phase IIb trial of brilacidin in ABSSSI
Read More
Biothera announces phase Ib trial of mucin-1-targeted antibody BTH-1704 and Imprime PGG
Read More
Bristol-Myers Squibb reports pipeline progress of third quarter 2014
Read More
GSK seeks approval of additional indications for lamotrigine in Japan
Read More
RPL-554 in combination with MRP4 blocker as potential adjunct therapy for CF
Read More
Researchers present new genetic animal models of disease
Read More
CSL Limited to acquire Novartis influenza vaccines business
Read More
Aileron Therapeutics begins phase I/II study of ALRN-6924
Read More
CHMP recommends approval of Duavive
Read More
Preclinical efficacy of a selective HSP90alpha/beta-inhibitor against MM
Read More
Octagam 10% now available in the U.S. for chronic ITP
Read More
Orion Corp. discloses new FGF-1 inhibitors
Read More
Temple University divulges new 5-HT7 receptor antagonists
Read More
Bristol-Myers Squibb patents new HIV integrase inhibitors
Read More
Takeda Pharmaceutical discloses novel CH24H inhibitors
Read More
Bristol-Myers Squibb presents results of the phase III HALLMARK-QUAD trial
Read More
Novel compounds for tuberculosis disclosed by Charles University
Read More
EMA committee recommends approval for Rixubis in patients with hemophilia B
Read More
Pembrolizumab given FDA Breakthrough Therapy Designation for NSCLC
Read More
Cocrystal Pharma develops Ebola high-throughput screening technology
Read More
Akebia releases topline results from phase IIb study of AKB-6548 in patients with CKD and anemia
Read More
